Journal
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 125, Issue 2, Pages S95-S102Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2009.10.047
Keywords
Asthma; respiratory syncytial virus; rhinovirus; allergen; prevention; exacerbation; inception; treatment
Categories
Funding
- National Institutes of Health [1P01HL70831-01, HL56396, AI50500]
- Novartis
- Centocor
- GlaxoSmithKline
- MedImmune
- Ception
- National Institutes of Health-National Institute of Allergy and Infectious Diseases
- National Heart, Lung, and Blood Institute
Ask authors/readers for more resources
Asthma is a complex disorder that displays heterogeneity and variability in its clinical expression both acutely and chronically. This heterogeneity is influenced by multiple factors including age, sex, socioeconomic status, race and/or ethnicity, and gene by environment interactions. Presently, no precise physiologic, immunologic, or histologic characteristics can be used to definitively make a diagnosis of asthma, and therefore the diagnosis is often made on a clinical basis related to symptom patterns (airways obstruction and hyperresponsiveness) and responses to therapy (partial or complete reversibility) over time. Although current treatment modalities are capable of producing control of symptoms and improvements in pulmonary function in the majority of patients, acute and often severe exacerbations still occur and contribute significantly to both the morbidity and mortality of asthma in all age groups. This review will highlight some of the important clinical features of asthma and emphasize recent advances in both pathophysiology and treatment. (J Allergy Clin Immunol 2010;125:S95-102.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available